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30Objectives: A minimal-dose computed tomography scan of the thorax (MnDCT) delivers a radiation dose
comparable with a chest x-ray (CXR). We hypothesized that in patients with completely resected lung cancer,
surveillance with MnDCT, when compared with CXR, leads to earlier detection and a higher rate of treatment of
new or recurrent lung cancer.
Methods:After lung cancer resection, patients prospectivelywere enrolled for surveillancewithMnDCTandCXR
at 3, 6, 12, 18, 24, 36, 48, and 60 months. Images were interpreted by different blinded radiologists. When new or
recurrent cancer was suspected, standard-dose CT and/or a tissue biopsy were performed for confirmation.
Results: Between 2007 and 2012, 271 patients were included and 1137 pairs of CXR and MnDCT were
analyzed. MnDCT was more sensitive (94% vs 21%; P<.0001) and had a higher negative predictive value
(99% vs 96%; P ¼ .007) than CXR for the diagnosis of new or recurrent lung cancer. The prevalence of
new or recurrent lung cancer was 23.2% (63 of 271), of whom 78% (49 of 63) had asymptomatic disease.
The majority of asymptomatic patients (75%; 37 of 49) were treated with curative intent and had a median
survival of 69 months. The remainder of patients received palliative treatment (24%; 12 of 49) and had a median
survival of 25 months (P<.0001).
Conclusions: After curative resection of lung cancer, MnDCT is superior to CXR for the detection of
new or recurrent lung cancer. The majority of new or recurrent cancer was detected by MnDCT at an
asymptomatic phase, allowing for curative treatment, leading to a long survival. (J Thorac Cardiovasc
Surg 2014;147:30-5)Earn CME credits at
http://cme.ctsnetjournals.org
Survivors of lung cancer surgery are among the highest-risk
patients for developing another lung cancer, either a new
metachronous primary tumor (1%-2% per year risk) or
recurrent disease (10%-38% overall risk).1,2 Despite this,
there is no clear consensus on the follow-up evaluation of
patients after curative surgical resection of lung cancer.3
Although surveillance with periodic chest x-ray (CXR) is
indicated in most published guidelines,4 recent recommen-
dations for the use of a routine thoracic computede Division of Thoracic Surgery,a Department of Radiology,b and Division of
atistics,c University of Toronto, Toronto, Ontario, Canada.
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The Journal of Thoracic and Cardiovascular Surgetomography (CT) scan are starting to emerge.5 We hypoth-
esized that, after lung cancer resection, surveillance with
minimal-dose CT of the chest (MnDCT) leads to earlier
detection and a higher rate of treatment of new or recurrent
lung cancer, when compared with CXR.MATERIALS AND METHODS
After Institutional Review Board approval, patients who had under-
gone lung cancer resection were invited to participate in this prospective
study at the time of their first postoperative visit. Consenting patients
were seen in the clinic every 3 months for the first 2 years after surgery,
then every 6 months until 5 years after surgery, and then yearly thereafter.
Each patient underwent surveillance with both MnDCT of the thorax and
CXR at 3, 6, 12, 18, 24, 36, 48, and 60 months after surgery. Patients
remained on study protocol until they were diagnosed with new or
recurrent lung cancer, or until they had reached 5 years without evidence
of disease. All MnDCT scans were acquired with the use of 64-row
multidetector scanners (Aquilion 64; Toshiba Medical Systems, Ottawara,
Japan) using a tube potential of 120 kVp, a fixed tube current of 10 mA
with a gantry rotation of 500 ms, resulting in an average effective dose of
0.2 mSv. The average effective dose with standard-dose chest CT varies
widely but is approximately 8 mSv.6 Two-view digital chest radiography
was performed at an average effective dose of 0.16 mSv. All CXRs were
interpreted by subspecialty board certified thoracic radiologists who were
blinded to the MnDCT. The MnDCT images were interpreted by subspe-
cialty board certified chest radiologists who were blinded to the CXR.
The images and interpretation reports of both tests then were reviewed
by the thoracic surgeon. A test was termed ‘‘positive’’ when it wasry c January 2014
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suspicious for recurrent or new lung cancer. Common findings that led to
positive studies were noncalcified nodules, intrathoracic lymphadenopa-
thy, or pleural effusion. Whenever a positive study was reported, further
confirmatory investigations such as standard-dose high-resolution
thoracic CT and/or tissue biopsy were ordered at the discretion of the
treating surgeon. Patients with false-positive screening studies returned
to surveillance per study protocol. Patients with a confirmed diagnosis
of cancer were restaged and treated with either curative or palliative
intent per the recommendation of a multidisciplinary tumor board.
The gold standard for calculating sensitivity was the pathologic spec-
imen in patients who underwent biopsy or surgery, and the administration
of lung cancer treatment in patients who did not achieve a pathologic
diagnosis. When the diagnosis of lung cancer was confirmed, all prior
MnDCT scans were reviewed to determine whether they were false
negatives or true positives.
Statistical analysis was performed using SPSS software version 20
(SPSS Inc, Chicago, Ill). Continuous variables were described using
mean and standard deviation and categoric variables using frequency and
percentage. Logistic regression analysis was used to compare diagnostic
performance measures between the 2 imaging modalities and generalized
estimating equations were used to adjust for correlations of repeated
measures. Kaplan-Meier survival analysis was performed; survival curves
and estimates of median survival time are provided. The log-rank test was
used for comparison of survival functions. The level of significancewas set
at a P value less than .05.RESULTS
Demographics
Between 2007 and 2012, 311 patients were enrolled in the
study and 271 patients were analyzed. Forty patients were
excluded for the following reasons: voluntary withdrawal
(14 of 40), loss to follow-up evaluation (12 of 40), death
before the 3-month visit (8 of 40), recurrence before the
3-month visit (4 of 40), and development of non-lung cancer
requiring imaging and treatment (2 of 40). The mean age
was 66.6 9.5 years (range, 40-90 year), 53.5% of patients
were women, and the majority (79.7%) were smokers.
Pathologic staging of disease was performed according to
the 7th edition of the American Joint Committee on
Cancer/International Union Against Cancer (Union
Internationale Contre Cancer) TNM staging manual.7 Stage
I disease was found in 79.7% of patients, stage II in 12.5%
of patients, stage III in 6.6% of patients, and stage IV in
1.1% of patients. The majority of patients had a lobar
resection (77.9%), and 18.1% had a sublobar resection,
1.8% had a bilobectomy, and 2.2% had a pneumonectomy.
Video-assisted thoracoscopic surgery was used in 36.5% of
cases. Chemotherapy and radiation therapy were used in
21.4% and 12.5% of patients, respectively.The Journal of Thoracic and CDiagnostic Performance of MnDCT Versus CXR
A total of 1137 pairs of MnDCTand CXRwere analyzed.
The sensitivity of MnDCT for the diagnosis of new or
recurrent lung cancer after surgical resection was 94.2%
(95% CI, 84.1-98.8) versus 21.2% for CXR (95% CI,
11.1-34.72; P<.0001). There were no cancers diagnosed
on CXR that were not detected on MnDCT. When no signs
of lung cancer were detected, the negative predictive
value of MnDCTwas 99.7% (range, 99.0%-99.9%) versus
96.2% (range, 94.9%-97.2%) for CXR (P ¼ .007).
MnDCT has a specificity of 86% (range, 83.7%-88.1%)
and a positive predictive value of 25.1% (range, 19.2%-
31.8%) for the diagnosis of new or recurrent lung cancer,
versus 99.9% (range, 99.5%-99.9%) and 91.7% (range,
61.5%-99.8%), respectively, for CXR (P<.0001).Patterns of Further Investigation After Positive
MnDCT
Positive MnDCT screening studies led to further
investigation by the surgeon in only 54.4% of cases. Further
tests consisted of standard-dose CTof the chest in 79.1% of
cases and invasive procedures (bronchoscopy or CT-guided
biopsy) in only 20.9%. Further investigations were not
pursued in 45.6% of positive MnDCT studies, in which
the surgeon used clinical judgment to classify the result as
a false positive. This judgment was correct in 81% of cases,
as evidenced by further follow-up evaluation.Patterns of Recurrent or New Lung Cancer
New or recurrent lung cancer was confirmed in 23.2% (63
of 271) of patients. Amongmultiple risk factors analyzed in a
multivariate logistic regression model, bilobar resection and
stage III diseasewere identified as predictors of recurrence or
new lung cancer, whereas multiple nodules and male sex
showed a trend toward statistical significance (Table 1).
The majority of patients with cancer (77.8%; 49 of 63)
presented with asymptomatic disease that was diagnosed
only by imaging (Figure 1). Two thirds of patients (67.3%;
32 of 49) were diagnosed on MnDCT within the first year
of surveillance, and 26.5% (13 of 49) were diagnosed within
the second year. No asymptomatic patients were diagnosed
in the fourth and fifth year (Figure 2). Symptomatic disease
was diagnosed in 22.2% (14 of 63). At the present time,
52.4% (142 of 271) of patients remain disease free with
a median follow-up period of 36 months, and 24.3%
(66 of 271) are disease free at 5 years (Figure 1).Patterns of Treatment and Survival
The majority of patients with asymptomatic new or
recurrent lung cancer (75.5%; 37 of 49) were found to be
candidates for curative treatment with further surgery or
radiation. Themedian survival for patients whowere treated
with curative intent was 69 months (range, 12-76 months)ardiovascular Surgery c Volume 147, Number 1 31
TABLE 1. The predictors of recurrent or new lung cancer after
surgical resection
Risk factors
Odds
ratio
95% Confidence
interval
P
value
Bilobar resection 6.813 1.108-41.89 .048
Stage III 2.962 1.157-7.584 .036
Multiple pulmonary nodules 2.205 0.982-4.951 .05
Male sex 1.845 0.995-3.423 .05
Age — — .07
Chemotherapy treatment — — .43
Radiotherapy treatment — — .22
History of other cancer — — .12
Continued to smoke — — .60
FIGURE 2. Distribution over time (in months) of the recurrences or new
cancers diagnosed by MnDCT.
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patients who presented with symptomatic disease (14 of
14) were found to be ineligible for curative intent therapy.
These patients were referred to treatment with palliative
intent and had a median survival of 15 months (range,
7-63 months) from the initial surgery. In addition, 24.5%
(12 of 49) of patients with asymptomatic disease also
were not candidates for further curative treatment and
therefore were treated with palliative intent, with a median
survival of 25 months (range, 6-48 months). The survival of
patients who were referred to palliative treatment was
significantly shorter than the survival of patients treated
with curative intent (P<.0001) (Figure 3).DISCUSSION
Screening trials have shown that CT is superior to CXR in
detecting early stage lung cancer. However, survivors of
lung cancer were excluded from these studies and it is still
unknown how CT compares with CXR in postoperative
surveillance.8-16 In this prospective blinded study, we
compared MnDCT with CXR in the follow-up period after
lung cancer resection. The trial was designed to minimize
bias by using the same patient population for the interven-
tion (MnDCT) and the control (CXR) arms. We show that
MnDCT is vastly superior to CXR in the detection of new
or recurrent lung cancer. More importantly, the advantageFIGURE 1. Clinical pathways of patients who were diagnosed with new
or recurrent lung cancer during surveillance.
32 The Journal of Thoracic and Cardiovascular Surgein sensitivity of MnDCT did not come at the cost of higher
radiation exposure because the effective radiation dose
(0.2 mSv) was comparable with that of CXR (0.16 mSv).
However, high sensitivity comes at the expense of low
positive predictive value, which has been documented
in previous CT screening trials.15,17,18 Nevertheless, at our
institution, surgeons were able to recognize false-positive
results with higher accuracy than radiologists and only
half of the positive MnDCT studies led to further investiga-
tion. This is consistent with previous studies on the
surgeon’s ability to use clinical judgment in interpreting
an oversensitive screening test, and highlights the surgeon’s
active role in decreasing the potential cost and morbidity of
overinvestigation.17
Extrathoracic metastatic disease, especially to the brain,
has been considered the most common site of recurrence in
patients with resected lung cancer.19-21 In contrast, we have
shown that with MnDCT, the majority of patients can beFIGURE 3. Survival in months since initial surgery.
ry c January 2014
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within 2 years of surgery, when potentially curative
intervention still is possible. Other investigators have
shown that, in patients with previously resected lung
cancer, curative surgery for a second lung cancer can be
associated with a 5-year survival rate of 60%.22,23 In this
study, the majority of asymptomatic patients were offered
curative treatment that was associated with a median
survival of more than 5 years, suggesting that efforts
directed toward early intervention are associated with
encouraging survival in a subset of patients with
asymptomatic disease.
There were several limitations to this study. Although
MnDCT can be performed in any setting, the radiologists
at our hospital have extensive experience in interpreting
low-dose and ultra-low-dose images, and this may not be
generalizable to other institutions. MnDCT is unable to
distinguish between new and recurrent lung cancer, a
distinction that is important in terms of prognosis.18,24 In
addition, lead time and length time bias can falsely
improve outcomes for asymptomatic patients detected
early by MnDCT. Finally, because of small numbers and
ongoing follow-up evaluation, this study may not be able
to answer the question of whether MnDCT screening after
lung cancer resection will improve survival in patients
who are in remission.CONCLUSIONS
MnDCT is superior to CXR for the detection of new or
recurrent lung cancer after curative resection of a previous
lung cancer. Themajority of newor recurrent cancerswas de-
tected by MnDCT at an asymptomatic, intrathoracic stage,
within 2 years of surgery. This allowed for the delivery of
curative treatment in themajority of patientswith asymptom-
atic cancer and was associated with long survival.References
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Discussion
Dr Michael T. Jaklitsch (Boston, Mass). Thank you very
much. It is my privilege to discuss this remarkable paper by
Dr Hanna and his colleagues at the University of Toronto on
minimal-dose CT scan for screening of lung cancer recurrence
in those patients who have undergone a successful surgical
operation for early stage lung cancer.
Last year at this meeting the AATS task force for lung cancer
screening and surveillance reported its guidelines for screeningardiovascular Surgery c Volume 147, Number 1 33
General Thoracic Surgery Hanna et al
G
T
Sfor new populations, but also it was our specific mandate to address
what should be done for screening for surveillance of lung cancer
survivors. We were struck by the paucity of hard scientific data to
draw upon our guidelines and resorted to anecdotal experience of
large centers that had a vast experience, including following the
traditions that were established at the University of Toronto in
the 1980s. I congratulate Dr Hanna and his colleagues for now
providing that surgical evidence that gives meat to the specific
guidelines.
Screening for early stage lung cancer with minimal harm and
maximum benefit is an interaction of several variables, including
the baseline risk of the screened population, the interval of
screening, and the technology of screening. Dr Hanna shows that
this particular population is the highest risk, in fact, a 10% risk
over 5 years. That is twice the risk of what we normally deem as
a high-risk subpopulation of 5% over 5 years, and the NLST
data, which showed a 20% reduction in lung cancer-specific
mortality, had a 2% risk over 5 years.
Furthermore, he has technology that is really impressive.
Dropping that mSv dose down to 0.2, so it really is comparable
to chest x-ray, eliminates the potential harms of the operation,
and they combine this to now introduce the idea of surgical salvage
for early stage lung cancer. So, in fact, they were able to take a
group that would have had a 5-year survival of 50% and raise it
up to 75% through an aggressive surveillance program, and,
furthermore, they established that they were truly curing these
patients.
Is this enough data to change our personal practices today? For
me personally the answer is yes. This single paper presents to me
enough data to say that I want to use aminimal-dose CT scan as my
sole method of screening for recurrence of early stage lung cancer
moving forward. And although he states that minimal-dose CT is
not available at every center in the United States, I was able to take
the specifications that Dr Hanna provided me with in his paper to
my community hospital, and my community hospital assures me
that they can do this. So, at least in the United States of America,
I think that this will have dramatic penetrance.
My specific question, Dr Hanna, is, are there other variables that
come into play that may limit this technology? In particular, one of
the issues is scatter of the x-ray beam. If I have a very heavyset
patient who has a BMI of, say, 40, is this technology going to
work or am I going to have to increase the dose? What if I have
a lot of surgical clips at the hilum? Is that going to produce scatter?
Do you at least have some anecdotal evidence that suggests that
there is a subpopulation in which this will not work?
Thank you for the privilege of discussing this paper.
Dr Hanna. Thank you for your comments, Dr Jaklitsch, and
for taking the time to discuss our paper. Your question is very
important because a lot of radiologists and surgeons ask us about
the accessibility of minimal dose in terms of interpretation. There
are certain limitations to the minimal-dose technology. You
mentioned patients of a particular body habitus and a high BMI.
These are problematic because the noise on the CT scan image
is usually very high and then you cannot really see small detail.
So, in these patients, one would recommend a low-dose CT rather
than minimal-dose CT, at least at our institution. Other limitations
of minimal-dose CTwould be mediastinal imaging. If you have a
patient in whom you are suspecting a high recurrence rate in the34 The Journal of Thoracic and Cardiovascular Surgemediastinum, such as a patient who had a resected tumor where
there was mediastinal involvement or close margins, then our
radiologists feel more comfortable with low-dose CT rather than
minimal-dose CT for the surveillance of these patients. You also
mentioned surgical clips in the area which contribute to the noise
and make minimal-dose CT less sensitive.
Dr Bryan Fitch Meyers (St. Louis, Mo). That was an excellent
paper. I am not likely to be quite as quick to adopt it as Dr Jaklitsch,
but I would be happy to study the process. I have one question:
with early stage (I/II) lung cancer, we expect about 20% to recur
systemically, and about 2% per year to develop a new primary
tumor. If your results presented today are applicable to the general
population of resected lung cancer patients, it would be reassuring
to know that you found the same rate of recurrence and new
primaries in your patients, or did you have an enriched population
by somehow selecting higher-risk patients?
DrHanna. Thank you. This is a very important question. As we
have demonstrated, most of our patients were stage I disease. So
we did find a lower rate of systemic recurrence than what we
expected in a general population of all-comers. However, we do
think that surveillance with minimal-dose CTwill shift those rates
of recurrence or new primary tumors.We do not make a distinction
between recurrence or new primary because we do not think that in
terms of surveillance it matters—these patients are at high risk for
both events.
DrChumyNwogu (Buffalo, NY). My question arises from your
calculation of sensitivity for your minimal-dose CT. What did you
use as your gold standard to do that calculation and did you have
a direct comparison between the regular CT scan and your
minimal-dose CT to see what the differences would be? I think
that would help us tremendously in deciding whether to adopt
this in our daily practices.
Dr Hanna. Thank you very much. It is a very important point.
We did not have a direct comparison between standard-dose CT
and minimal-dose CT, but our gold standard of determining
whether a patient recurred or not was most of the time a
standard-dose CT. When a minimal-dose CT study was deemed
positive by the radiologist and the surgeon, the patient would go
on to a standard-dose CT, and if the findings were suspicious
enough for recurrence, the patient would be biopsied, restaged,
or treated. So most of the time the standard-dose CT was a
reference point to calculate sensitivity.
In patients who we still missed on standard-dose CT, the
eventual development of metastatic disease or local recurrent
disease was considered as the reference point, and in patients
who were treated palliatively because of enough suspicion on
imaging that they had recurrent or metastatic disease, then this
was our reference point. Thank you.
Dr Frank C. Detterbeck (New Haven, Conn). I think this is a
very exciting paper. I am struck, though, that your incidence of
finding a lesion early is quite high, and there are many institutions
that have done CT scans every 6 months or every year. I am sure
you have done that in the past. Have you compared this with either
your prior results or other institutional results at a year, because
those that were found at 3, 6, 9, and 12 months should have shown
up at the yearly scan.
Dr Hanna. Thank you very much. We still do not know exactly
the ideal interval for obtaining scans. Is it 3months or 6months or ary c January 2014
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is part of the international consensus statement, and I do agree that
some of the lesions that we found at 3 months or 6 months could
have been found at a year if we did a yearly scan without much
difference in outcome. So this remains to be studied.
But I do think it is also important to recognize that now there is a
shift in terms of when we diagnose recurrence or new primary after
lung cancer, and it is going to be earlier and earlier.
Dr David J. Sugarbaker (Boston, Mass). Just a quick question,
and that is, what you have really described is the detection of
new primary tumors following initial resection. Particularly in
T2 tumors, the 2 sites of recurrence where long-term therapy is
usually not associated with prolonged survival are, as you said,
mediastinal node disease and distant metastatic disease. So I think
it is important to realize that what you are really talking about
here is screening patients who have had lobar resections or any
resections for lung cancer.The Journal of Thoracic and CSo I am not sure your conclusion about follow-up detection
of metastatic disease is really an accurate description as to
what you have done. And, particularly with the inability of
minimal-dose CT to assess the mediastinum, particularly in
the larger lesions where distant metastatic disease may be
more frequent, I am not sure that minimal dose CT is adequate
for those patients where, again, mediastinal nodal disease can
be the real issue.
Could you comment?
Dr Hanna. Thank you. I do agree with that. I think mini-
mal-dose CT is a good test for detection of a new primary.
However, we realize that these patients are also at risk
for mediastinal disease, and I think the future will hold a
more patient-centered approach to follow-up whereby patients
with a higher risk of distant recurrence will have some other
tests on top of the minimal-dose CT to try and detect that
earlier.ardiovascular Surgery c Volume 147, Number 1 35
